Steven Nijs

1.3k total citations
24 papers, 562 citations indexed

About

Steven Nijs is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Steven Nijs has authored 24 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 18 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Steven Nijs's work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (13 papers). Steven Nijs is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (18 papers) and HIV/AIDS Research and Interventions (13 papers). Steven Nijs collaborates with scholars based in United States, Belgium and France. Steven Nijs's co-authors include Johan Vingerhoets, Gastón Picchio, Lotke Tambuyzer, Brian Woodfall, Hilde Azijn, Marie‐Pierre de Béthune, Goedele De Smedt, Annemie Hoogstoel, Monika Peeters and James Witek and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and AIDS.

In The Last Decade

Steven Nijs

22 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Nijs United States	12	548	443	106	52	51	24	562
Ian McGowan United States	6	464 0.8×	362 0.8×	108 1.0×	25 0.5×	41 0.8×	11	492
Greet Beets United States	6	364 0.7×	298 0.7×	123 1.2×	60 1.2×	40 0.8×	8	430
Amelia S. Petry United States	7	367 0.7×	209 0.5×	119 1.1×	64 1.2×	44 0.9×	9	423
Romina Quercia United Kingdom	10	408 0.7×	335 0.8×	75 0.7×	27 0.5×	66 1.3×	16	491
Naomi Givens United Kingdom	9	566 1.0×	399 0.9×	107 1.0×	28 0.5×	35 0.7×	17	609
Rosa Ruiz-Valderas Spain	12	342 0.6×	160 0.4×	189 1.8×	46 0.9×	45 0.9×	26	457
A Moll Germany	7	359 0.7×	272 0.6×	136 1.3×	87 1.7×	35 0.7×	7	420
Kati Vandermeulen Belgium	12	651 1.2×	480 1.1×	133 1.3×	35 0.7×	45 0.9×	19	713
L. Trentini Italy	11	257 0.5×	137 0.3×	78 0.7×	63 1.2×	35 0.7×	25	354
Yvon van Delft Netherlands	12	440 0.8×	354 0.8×	79 0.7×	27 0.5×	12 0.2×	28	481

Countries citing papers authored by Steven Nijs

Since Specialization

Citations

This map shows the geographic impact of Steven Nijs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Nijs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Nijs more than expected).

Fields of papers citing papers by Steven Nijs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Nijs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Nijs. The network helps show where Steven Nijs may publish in the future.

Co-authorship network of co-authors of Steven Nijs

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Nijs. A scholar is included among the top collaborators of Steven Nijs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Nijs. Steven Nijs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Böhmig, Georg A., Mark Haas, Philip F. Halloran, et al.. (2025). Trial Design of the Phase 2 Study SHAMROCK Evaluating the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Kidney Transplant Recipients with Antibody-Mediated Rejection. American Journal of Transplantation. 25(8). S698–S698.

Orrell, Catherine, Franco Felizarta, Thomas N. Kakuda, et al.. (2015). Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. AIDS Research and Treatment. 2015. 1–11. 4 indexed citations

Tambuyzer, Lotke, Kim Thys, Annemie Hoogstoel, et al.. (2015). Assessment of Etravirine Resistance in HIV-1-Infected Paediatric Patients using Population and Deep Sequencing: Final Results of the PIANO Study. Antiviral Therapy. 21(4). 317–327. 2 indexed citations

Tudor‐Williams, Gareth, Pedro Cahn, Kulkanya Chokephaibulkit, et al.. (2014). Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine. 15(9). 513–524. 19 indexed citations

Orrell, Catherine, Franco Felizarta, Thomas N. Kakuda, et al.. (2013). Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial. 1 indexed citations

Kakuda, Thomas N., Goedele De Smedt, Lorant Leopold, et al.. (2013). Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies. International Journal of Clinical Pharmacology and Therapeutics. 51(9). 725–736. 8 indexed citations

Vingerhoets, Johan, L Rimsky, Veerle Van Eygen, et al.. (2012). Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response. Antiviral Therapy. 18(2). 253–256. 31 indexed citations

Kakuda, Thomas N., Rodica Van Solingen‐Ristea, Goedele De Smedt, et al.. (2012). Pharmacokinetics and Short‐Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV‐Negative Volunteers. The Journal of Clinical Pharmacology. 53(1). 41–50. 9 indexed citations

Vingerhoets, Johan, Steven Nijs, Lotke Tambuyzer, et al.. (2012). Similar Predictions of Etravirine Sensitivity Regardless of Genotypic Testing Method Used: Comparison of Available Scoring Systems. Antiviral Therapy. 17(8). 1571–1579. 12 indexed citations

10.

Tambuyzer, Lotke, et al.. (2011). Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 58(1). 18–22. 60 indexed citations

11.

Tambuyzer, Lotke, Johan Vingerhoets, Hilde Azijn, et al.. (2010). Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies. AIDS Research and Human Retroviruses. 26(11). 1197–1205. 45 indexed citations

12.

Vingerhoets, Johan, Hilde Azijn, Lotke Tambuyzer, et al.. (2010). Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data. AIDS Research and Human Retroviruses. 26(6). 621–624. 11 indexed citations

13.

Clumeck, Nathan, et al.. (2010). Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. Journal of Antimicrobial Chemotherapy. 65(11). 2450–2454. 10 indexed citations

14.

Kakuda, Thomas N., Janet R. Wade, Eric Snoeck, et al.. (2010). Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. Clinical Pharmacology & Therapeutics. 88(5). 695–703. 37 indexed citations

15.

Towner, William, Jacob Lalezari, Michael Sension, et al.. (2010). Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(5). 614–618. 16 indexed citations

16.

Vingerhoets, Johan, Lotke Tambuyzer, Hilde Azijn, et al.. (2010). Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 24(4). 503–514. 137 indexed citations

17.

Clumeck, Nathan, Pedro Cahn, Jean‐Michel Molina, et al.. (2010). Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials. International Journal of STD & AIDS. 21(11). 738–740. 3 indexed citations

18.

Towner, William, Isabel Cassetti, Peré Domingo, et al.. (2010). Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antiviral Therapy. 15(6). 803–816. 5 indexed citations

19.

Katlama, Christine, Bonaventura Clotet, Anthony Mills, et al.. (2010). Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy. 15(7). 1045–1052. 85 indexed citations

20.

Campbell, Thomas L., et al.. (2009). Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact